| Literature DB >> 29343988 |
Boyoung Park1,2, Hye Mi Cho2, Eun Hye Lee3, Seunghoon Song2, Mina Suh2, Kui Son Choi1,2, Bong Joo Kang4, Kyungran Ko5, Ann Yi6, Hae Kyoung Jung7, Joo Hee Cha8, Jae Kwan Jun1,2.
Abstract
PURPOSE: The purpose of this study was to investigate the effects of breast density on breast cancer risk among women screened via a nationwide mammographic screening program. PATIENTS AND METHODS: We conducted a nested case-control study for a randomly selected population of 1,561 breast cancer patients and 6,002 matched controls from the National Cancer Screening Program. Breast density was measured and recorded by two independent radiologists using the Breast Imaging Reporting and Data System (BI-RADS). Associations between BI-RADS density and breast cancer risk were evaluated according to screening results, time elapsed since receiving non-recall results, age, and menopausal status after adjusting for possible covariates.Entities:
Keywords: breast cancer; breast density; breast imaging reporting and data system; nationwide mammographic screening program
Year: 2017 PMID: 29343988 PMCID: PMC5749627 DOI: 10.2147/CLEP.S144918
Source DB: PubMed Journal: Clin Epidemiol ISSN: 1179-1349 Impact factor: 4.790
Baseline characteristics of breast density and selected risk factors of breast cancer of 1,561 pairs of breast cancer cases and matched controls
| Characteristics | Incident breast cancer cases | Matched controls | |
|---|---|---|---|
| Age, mean (standard deviation), years | 53.0 (8.7) | 53.0 (8.7) | 0.97 |
| Age at menarche, n (%) | |||
| ≤13 years | 163 (10.4) | 470 (7.8) | <0.001 |
| 14–16 years | 871 (55.8) | 3258 (54.3) | |
| ≥17 years | 454 (29.1) | 2113 (35.2) | |
| Missing | 73 (4.7) | 161 (2.7) | |
| Number of live births, n (%) | |||
| 0 | 106 (6.8) | 271 (4.5) | <0.001 |
| 1 | 208 (13.3) | 581 (9.7) | |
| ≥2 | 1208 (77.4) | 5065 (84.4) | |
| Missing | 39 (2.5) | 85 (1.4) | |
| Breast feeding, n (%) | |||
| 0 | 247 (15.8) | 715 (11.9) | <0.001 |
| <12 months | 410 (26.3) | 1777 (29.6) | |
| ≥12 months | 876 (56.1) | 3433 (57.2) | |
| Missing | 28 (1.8) | 77 (1.3) | |
| Age at menopause, n (%) | |||
| Premenopausal | 369 (23.6) | 1613 (26.9) | 0.187 |
| <45 years | 76 (4.9) | 336 (5.6) | |
| 45–54 years | 868 (55.6) | 3316 (55.3) | |
| ≥55 years | 109 (7.0) | 408 (6.8) | |
| Missing | 139 (8.9) | 329 (5.5) | |
| Hormone replacement therapy, n (%) | |||
| Never | 667 (58.2) | 2935 (68.5) | 0.215 |
| Ever | 169 (14.7) | 660 (15.4) | |
| Missing | 311 (27.1) | 688 (16.1) | |
| Oral contraceptive use, n (%) | |||
| Never | 866 (55.5) | 4061 (67.7) | 0.053 |
| <12 months | 92 (5.9) | 519 (8.6) | |
| ≥12 months | 70 (4.5) | 258 (4.3) | |
| Missing | 533 (34.1) | 1164 (19.4) | |
| Body mass index, n (%) | |||
| <23 kg/m2 | 496 (31.8) | 1951 (32.5) | 0.476 |
| 23 to <25 kg/m2 | 292 (18.7) | 1225 (20.4) | |
| ≥25 kg/m2 | 360 (23.1) | 1357 (22.6) | |
| Missing | 413 (26.5) | 1469 (24.5) | |
| Past history of benign breast disease, n (%) | |||
| No | 884 (56.6) | 4962 (82.7) | <0.001 |
| Yes | 498 (31.9) | 526 (8.8) | |
| I do not know | 179 (11.5) | 514 (8.5) | |
| Breast density, n (%) | |||
| Almost entirely fat | 122 (7.8) | 1001 (16.7) | <0.001 |
| Scattered fibroglandular densities | 352 (22.6) | 1564 (26.1) | |
| Heterogeneously dense | 667 (42.7) | 2258 (37.6) | |
| Extremely dense | 420 (26.9) | 1179 (19.6) |
Breast density as risk factor of breast cancer according to the age groupa
| Results
| All results
| 40–49 years of age
| 50–59 years of age
| 60–69 years of age
| 70+ years of age
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Density | Case/control | OR | 95% CI | Case/ control | OR | 95% CI | Case/ control | OR | 95% CI | Case/ control | OR | 95% CI | Case/ control | OR | 95% CI |
| Almost entirely fat | 122/1001 | 1.0 | 4/85 | 1.0 | 27/314 | 1.0 | 60/407 | 1.0 | 31/195 | 1.0 | |||||
| Scattered fibroglandular densities | 352/1564 | 2.4 | 1.8–3.1 | 56/349 | 4.4 | 1.5–13.2 | 143/692 | 2.8 | 1.7–4.6 | 113/421 | 2.0 | 1.3–2.9 | 40/102 | 2.2 | 1.1–4.2 |
| Heterogeneously dense | 667/2258 | 3.8 | 2.9–4.9 | 286/1126 | 7.0 | 2.4–20.3 | 265/847 | 4.8 | 2.9–7.7 | 96/237 | 2.7 | 1.7–4.4 | 20/48 | 2.5 | 1.1–6.0 |
| Extremely dense | 420/1179 | 5.0 | 3.7–6.7 | 277/839 | 9.4 | 3.2–27.4 | 128/309 | 6.0 | 3.5-10.1 | 15/29 | 5.1 | 2.1–12.2 | 0/2 | – | – |
| <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |||||||||||
Note:
ORs are adjusted for age, age at menarche, number of live births, breast feeding, menopausal status/age at menopause, hormone replacement therapy use, oral contraceptive use, body mass index, past benign breast disease, and calculated by conditional logistic regression.
Abbreviations: CI, confidence interval; OR, odds ratio.
Figure 1Breast density as risk factor of breast cancer according to menopausal status. Odds ratios are adjusted for age, age at menarche, number of live births, breast feeding, menopausal status/age at menopause, hormone replacement therapy use, oral contraceptive use, body mass index, past benign breast disease and calculated by logistic regression. In total, 139 cases and 329 controls whose menopausal status were missing were excluded from analysis.
Breast density as risk factor of breast cancer according to screening results, assessment category, and time interval after non-recall screeninga
| Density
| Almost entirely fat
| Scattered fibroglandular densities
| Heterogeneously dense
| Extremely dense
| ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assessment categories | Case/ control | OR | Case/ control | OR | 95% CI | Case/ control | OR | 95% CI | Case/ control | OR | 95% CI | |
| Recall | 102/763 | 1.0 | 277/1162 | 2.2 | 1.7–3.0 | 462/1421 | 3.6 | 2.6–4.8 | 224/760 | 3.3 | 2.3–4.6 | <0.001 |
| Categories 4 and 5 (N=402 pairs) | 60/351 | 1.0 | 114/423 | 2.0 | 1.3–2.9 | 153/462 | 2.6 | 1.7–4.0 | 75/316 | 1.8 | 1.1–3.1 | 0.030 |
| Category 0 (N=663 pairs) | 42/412 | 1.0 | 163/739 | 2.9 | 1.9–4.3 | 309/959 | 4.9 | 3.2–7.6 | 149/444 | 5.2 | 3.2–8.4 | <0.001 |
| 0.203 | 0.040 | 0.003 | ||||||||||
| Non-recall | 20/238 | 1.0 | 75/402 | 3.0 | 1.6–5.5 | 205/837 | 5.2 | 2.8–9.8 | 196/419 | 12.1 | 6.3–23.3 | <0.001 |
| Diagnosis <1 year after screening (N=312 pairs) | 14/158 | 1.0 | 42/245 | 3.3 | 1.5–7.1 | 121/529 | 5.4 | 2.5–11.9 | 135/267 | 16.7 | 7.3–38.5 | <0.001 |
| Diagnosis ≥1 year after screening (N=184 pairs) | 6/80 | 1.0 | 33/157 | 3.6 | 1.2–11.1 | 84/308 | 7.6 | 2.4–24.2 | 61/152 | 12.1 | 3.7–39.6 | <0.001 |
| 0.900 | 0.631 | 0.663 | ||||||||||
| 0.371 | 0.301 | 0.001 | ||||||||||
Notes:
ORs are adjusted for age, age at menarche, number of live births, breast feeding, menopausal status/age at menopause, hormone replacement therapy use, oral contraceptive use, body mass index, past benign breast disease and calculated by conditional logistic regression.
Including BI-RADS categories 4 and 5 (suspicious for malignancy) and 0 (need additional imaging or prior examinations).
Including BI-RADS categories 1 (negative) and 2 (benign).
P-heterogeneity between recalled cases and non-recalled cases.
Abbreviations: BI-RADS, Breast Imaging Reporting and Data System; CI, confidence interval; OR, odds ratio.
Breast density as risk factor of breast cancer according to results of screening, time interval after negative screening, type of breast cancer, and Surveillance, Epidemiology, and End Results stagea
| Density | Almost entirely fat
| Scattered fibroglandular densities
| Heterogeneously dense
| Extremely dense
| |
|---|---|---|---|---|---|
| OR | OR (95% CI) | OR (95% CI) | OR (95% CI) | ||
| All (N=1,332 pairs) | 1.0 | 2.2 (1.7–2.9) | 2.3 (2.6–4.5) | 4.6 (3.3–6.2) | <0.001 |
| Recall | 1.0 | 2.0 (1.5–2.7) | 3.1 (2.3–4.2) | 2.8 (1.9–4.0) | <0.001 |
| Categories 4 and 5 (N=375 pairs) | 1.0 | 1.8 (1.2–2.7) | 2.3 (1.5–3.6) | 1.7 (1.0–2.9) | 0.058 |
| Category 0 (N=558 pairs) | 1.0 | 2.6 (1.7–4.0) | 4.2 (2.7–6.6) | 4.3 (2.6–7.1) | <0.001 |
| Non-recall | 1.0 | 3.3 (2.8–12.1) | 5.8 (2.8–12.1) | 15.5 (7.3–33.2) | <0.001 |
| Diagnosis <1 year after screening (N=253 pairs) | 1.0 | 3.5 (1.4–8.8) | 6.8 (2.7–16.9) | 25.0 (9.4–66.3) | <0.001 |
| 4.5 (1.2–16.8) | 8.0 (2.1–31.0) | 13.5 (3.3–54.7) | |||
| Diagnosis ≥1 year after screening (N=146 pairs) | 1.0 | 0.001 | |||
| All (N=733) | 1.0 | 2.1 (1.5–3.1) | 3.1 (2.1–4.4) | 5.7 (3.8–8.7) | <0.001 |
| Recall | 1.0 | 1.9 (1.3–2.9) | 2.7 (1.8–4.1) | 3.1 (1.9–5.0) | <0.001 |
| Categories 4 and 5 (N=186 pairs) | 1.0 | 1.5 (0.9–2.7) | 2.1 (1.1–3.9) | 1.5 (0.7–3.2) | 0.102 |
| Category 0 (N=314 pairs) | 1.0 | 2.7 (1.5–4.8) | 3.8 (2.1–7.0) | 5.7 (2.9–11.4) | <0.001 |
| Non-recall | 1.0 | 3.5 (1.3–9.4) | 6.5 (2.3–18.3) | 28.5 (9.6–84.3) | <0.001 |
| 4.1 (1.1–14.9) | 10.4 (2.6–40.9) | 42.6 (10.3–175.6) | |||
| Diagnosis <1 year after screening (N=156 pairs) | 1.0 | <0.001 | |||
| 4.5 (0.6–33.5) | 5.2 (0.7–37.8) | 32.5 (3.8–280.7) | |||
| Diagnosis ≥1 year after screening (N=77 pairs) | 1.0 | <0.001 | |||
| All (N=479) | 1.0 | 2.1 (1.3–3.4) | 3.8 (2.3–7.1) | 3.5 (2.0–5.9) | <0.001 |
| Recall | 1.0 | 2.0 (1.8–3.3) | 3.4 (2.0–5.8) | 2.9 (1.6–5.3) | <0.001 |
| Categories 4 and 5 (N=151 pairs) | 1.0 | 1.9 (0.9–3.8) | 2.1 (1.0–4.5) | 1.6 (0.6–4.0) | 0.125 |
| Category 0 (N=197 pairs) | 1.0 | 2.7 (1.0–4.9) | 5.6 (2.5–12.8) | 4.4 (1.8–10.6) | <0.001 |
| Non-recall | 1.0 | 3.1 (0.9–10.5) | 5.7 (1.7–18.8) | 6.0 (1.7–21.4) | 0.001 |
| 3.0 (0.6–14.9) | 3.3 (0.8–14.9) | 7.9 (1.5–43.1) | |||
| Diagnosis <1 year after screening (N=75 pairs) | 1.0 | 0.002 | |||
| 13.7 (0.9–200.2) | 89.6 (4.9–999.9) | 24.4 (1.5–389.9) | |||
| Diagnosis ≥1 year after screening (N=56 pairs) | 1.0 | 0.100 | |||
| All (N=229 pairs) | 1.0 | 4.9 (2.1–11.9) | 11.2 (4.5–28.1) | 13.9 (5.3–36.8) | <0.001 |
| Recall | 1.0 | 9.4 (2.6–34.26) | 28.3 (7.1–112.8) | 33.2 (7.6–144.7) | <0.001 |
| Non-recall | 1.0 | 2.1 (0.6–7.9) | 4.1 (1.1–15.8) | 6.0 (1.5–24.8) | 0.001 |
Notes:
ORs are adjusted for age, age at menarche, number of live births, breast feeding, menopausal status/age at menopause, hormone replacement therapy use, oral contraceptive use, body mass index, past benign breast disease and calculated by conditional logistic regression.
Including BI-RADS categories 4 and 5 (suspicious for malignancy) and 0 (need additional imaging or prior examinations).
Including BI-RADS categories 1 (negative) and 2 (benign).
Only 40 were distant breast cancer cases.
Abbreviations: BI-RADS, Breast Imaging Reporting and Data System; CI, confidence interval; OR, odds ratio.